Exhibit 10.1

 

AMENDED AND RESTATED 
 PATENT LICENSE AGREEMENT

 

THIS AMENDED AND RESTATED PATENT LICENSE AGREEMENT (“Amended and Restated Agreement”) is entered into and effective as of this 30th day of June, 2015 (the “Restatement Date”), by and between GLAUKOS CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“GLAUKOS”), and DOSE MEDICAL CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“DOSE”).

 

RECITALS

 

A.                                    GLAUKOS and DOSE have entered into that certain Patent License Agreement dated March 30, 2010, as amended by that certain letter agreement dated July 19, 2012 (the “Original Agreement”) under which, among other things, each party has licensed the other party certain rights to certain patent and patent applications; and

 

B.                                    GLAUKOS and DOSE now wish to amend and restate the Original Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated to read, and the parties hereto agree, as follows:

 

1.                                      DEFINITIONS

 

For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

1.1.                            “Agreement” means the Original Agreement as amended and restated by this Amended and Restated Agreement, as hereafter amended from time to time in accordance with its terms.

 

1.2.                            “Biosensor” means any system and/or apparatus designed (i) to be implanted in or affixed to the human body (or any part thereof) and (ii) to monitor and/or measure at least one state or condition of the human body (or any part thereof) or any changes or other aspects affecting the human body (or any part thereof).

 

1.3.                            “Confidential Information” means any information that in any way relates to a party, including without limitation information regarding a party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results and contractual relationships; provided, however, that the term “Confidential Information” shall not include information: (i) that, at the time of disclosure, is generally available to the public; (ii) that, after disclosure hereunder, becomes generally available to the public, except as a result of a breach of this Agreement by the recipient of such information; (iii) that becomes available to the recipient of such information from a third party that is not legally or contractually prohibited by the disclosing party from disclosing such information; or (iv) that the recipient can demonstrate was developed by or for such recipient without the use of any of the Confidential Information of the disclosing party hereunder.

 

1











 

1.4.                            “Dose Field of Use” means (i) any and all applications of a Biosensor and/or (ii) any and all applications for the treatment of any disorder or disease (other than Glaucoma) primarily affecting the posterior segment of the eye (i.e. the back two-thirds of the eye that includes the anterior hyaloid membrane and all of the optical structures behind it: the vitreous humor, retina, choroid, and optic nerve), provided that such applications described in this clause (ii) do not include an apparatus that includes a drainage lumen unless the drainage lumen’s primary purpose is to relieve intraocular pressure caused by the administration of steroids, delivered by an apparatus implanted in or on the eye, to treat a disorder or disease primarily affecting the posterior segment of the eye and not associated with Glaucoma.

 

1.5.                            “Dose Licensed Patents” means any and all patents and patent applications listed in Exhibit A to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit A, including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Dose Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit A.

 

1.6.                            “Effective Date” means March 30, 2010.

 

1.7.                            “Glaukos Field of Use” means any and all applications for the treatment of (i) Glaucoma, including but not limited to therapies directed toward reducing intraocular pressure and/or reducing the death of retinal ganglion cells (i.e., neuroprotection) associated with Glaucoma) and/or (ii) any disorder or disease primarily affecting the anterior segment of the eye (i.e., the front third of the eye that includes the structures in front of the vitreous humor: the cornea, iris, ciliary body, the lens, the anterior chamber between the posterior surface of the cornea and the iris and the posterior chamber between the iris and the front face of the vitreous); provided that, such applications described in clauses (i) or (ii) above do not include a Biosensor.

 

1.8.                            “Glaukos Group 1 Licensed Patents” means any and all patents and patent applications listed in Exhibit B to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit B, including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 1 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit B.

 

2











 

1.9.                            “Glaukos Group 2 Licensed Patents” means any and all patents and patent applications listed in Exhibit C to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit C, including, but not limited to all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 2 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit C.

 

1.10.                     “Regulatory Information” means pre-clinical, clinical, manufacturing and testing data, protocols, and chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, safety, efficacy, bioequivalency, quality assurance, quality control and other information and data relating to any investigations, trials and/or the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for any product, including but not limited to, with respect to GLAUKOS, information relating to preliminary investigations and the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for the iStent® (a/k/a G1 device), iStent InjectTM (a/k/a G2 device), and iStent SupraTM (a/k/a G3 device) including but not limited to FDA application materials, safety and efficacy data, clinical trial protocols and reports, statistical analyses, communications with the FDA, etc.

 

1.11.                     “Term of Access” means the period commencing on the Effective Date and continuing through and including June 30, 2018; provided, however, that the end date of the Term of Access may be earlier as determined (i) by DOSE upon not less than sixty (60) days’ prior written notice to GLAUKOS, (ii) by GLAUKOS upon not less than one hundred eighty (180) days’ prior written notice to DOSE or (c) by mutual agreement of GLAUKOS and DOSE.

 

1.12.                     “Valid Claim” means a claim that (i) in the case of any issued and unexpired patent, has not been dedicated to the public, disclaimed, nor held invalid or unenforceable by a court or other government entity of competent jurisdiction in an unappealed or unappealable decision, or (ii) in the case of any patent application, (a) has not been cancelled, withdrawn or abandoned, without being refiled in another application, in the applicable jurisdiction, (b) shall not have been finally rejected by a governmental entity or other governmental action from which no appeal can be taken and (c) shall not have been pending for more than five (5) years in the United States Patent and Trademark Office or seven (7) years in a foreign patent office.  For purposes of this definition, the time period for which a claim is pending shall begin on the priority date for such claim, and shall continue until such claim is either issued or is no longer deemed to be a Valid Claim in accordance with the preceding sentence regardless of whether such claim is amended or refiled in another application in the applicable jurisdiction.  If a claim of a patent application which ceased to be a Valid Claim under clause (ii) of the preceding sentence due to the passage of time later issues as part of a patent described within clause (i) of the preceding sentence then it shall again be considered to be a Valid Claim effective as of the issuance of such patent.

 

3











 

2.                                      EXCLUSIVE LICENSE FROM DOSE TO GLAUKOS

 

2.1.                            Subject to Section 2.2, DOSE hereby grants to GLAUKOS a limited, exclusive (even as to DOSE), irrevocable, perpetual, fully paid-up, worldwide license under the Dose Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all methods, solely in the Glaukos Field of Use.  The license granted to GLAUKOS under this Section 2.1, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Dose Licensed Patents within the Dose Field of Use.  The license granted to GLAUKOS under this Section 2.1 includes the right to sublicense, provided that any such sublicense from GLAUKOS be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 2.2.

 

2.2.                            Neither GLAUKOS nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 2.1 above) infringe a Valid Claim of a Dose Licensed Patent; provided that, the foregoing of this Section 2.2 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

3.                                      EXCLUSIVE LICENSE FROM GLAUKOS TO DOSE

 

3.1.                            Subject to Section 3.2, GLAUKOS hereby grants to DOSE a limited, exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license under the Glaukos Group 1 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Dose Field of Use.  The license granted to DOSE under this Section 3.1, however, shall not limit GLAUKOS’ right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 1 Licensed Patents within the Glaukos Field of Use.  The license granted to DOSE under this Section 3.1 includes the right to sublicense, provided that any such sublicense from DOSE be restricted to the Dose Field of Use and subject to the terms of this Agreement, including without limitation Section 3.2.

 

3.2.                            Neither DOSE nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the anterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 3.1 above) infringe a Valid Claim of a Glaukos Group 1 Licensed Patent; provided that, the foregoing of this Section 3.2 shall not limit DOSE from seeking or obtaining any label indication for application(s) of a Biosensor.

 

4











 

4.                                      EXCLUSIVE LICENSE TO DOSE / LICENSE BACK TO GLAUKOS

 

4.1.                            GLAUKOS hereby grants to DOSE an exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of one or more claims of the Glaukos Group 2 Licensed Patents.

 

4.2.                            Subject to Section 4.3, DOSE hereby grants back to GLAUKOS a limited exclusive (even as to DOSE), irrevocable, fully paid-up, perpetual, worldwide sublicense, with the right to sublicense such sublicense rights, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Glaukos Field of Use.  The sublicense to GLAUKOS, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 2 Licensed Patents within the Dose Field of Use.  This sublicense includes the right for GLAUKOS to grant further sublicenses, provided that any such further sublicense be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 4.3.

 

4.3.                            Neither GLAUKOS nor its sublicencees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 4.2 above) infringe a Valid Claim of a Glaukos Group 2 Licensed Patent; provided that, the foregoing of this Section 4.3 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

5.                                      ASSIGNMENT OF RIGHTS

 

5.1.                            Each of GLAUKOS and DOSE shall have the right to assign in whole or in part its rights, obligations and licenses under this Agreement.

 

5.2.                            Each party shall have the right to assign any or all of its patents or other intellectual property licensed to the other party by this Agreement only if such assignment is expressly subject to the continuance of such license.

 

6.                                      REGULATORY APPROVAL; TECHNOLOGY LICENSE

 

6.1.                            Each party shall be solely responsible, at its sole cost and expenses, for identifying and obtaining, including testing or other procedures, any necessary regulatory or safety approvals or certifications (e.g., FDA and safety agencies) required for the marketing and sale by such party of its products in any country.  Nevertheless, each party will cooperate with the other party by providing, upon request, any Regulatory Information in its possession and control that could reasonably assist the other party to obtain approvals or certifications of its products.  Each party will further permit the other party and its sublicensees to expressly reference each party’s Regulatory Information in the other party’s filings to obtain such approvals or certifications of its products.

 

5











 

6.2.                            Each party acknowledges and agrees that Regulatory Information provided by the other party may contain Confidential Information belonging to the other party. Each party shall disclose its Confidential Information to the other party only on a confidential basis subject to the provisions of Section 13.9.  Any use or disclosure of the Confidential Information of a party under this Agreement, including but not limited to any reference by the other party to the Confidential Information of a party in the other party’s filings to obtain approvals or certifications, shall be designated as confidential.

 

6.3.                            GLAUKOS hereby grants to DOSE a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of GLAUKOS (including but not limited to Regulatory Information and Confidential Information of GLAUKOS), existing as of the Effective Date or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Dose Field of Use.  From time to time (including without limitation after the Term of Access), upon DOSE’s written request and expense, GLAUKOS shall promptly deliver to DOSE copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in Glaukos’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.4.                            DOSE hereby grants to GLAUKOS a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of DOSE (including but not limited to Regulatory Information and Confidential Information of DOSE), existing as the Effective Date and/or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Glaukos Field of Use.  From time to time (including without limitation after the Term of Access), upon GLAUKOS’s written request and expense, DOSE shall promptly deliver to GLAUKOS copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in DOSE’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.5.                            Notwithstanding anything herein to the contrary, the rights and obligations of each party set forth Sections 6.1, 6.2, 6.3 and 6.4 shall not pertain to any data or other information arising from investigations or clinical trials conducted after the Term of Access but shall continue to pertain to all other Regulatory Information, including but not limited to any regulatory applications filed after the Term of Access to the extent based on data or information existing as of the Effective Date and/or during the Term of Access.

 

6











 

7.                                      OWNERSHIP

 

7.1.                            DOSE acknowledges that GLAUKOS is the sole owner of the Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents, and DOSE agrees that it does not obtain any interest in such patents except for the rights granted herein.  DOSE agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by GLAUKOS of such patents, or GLAUKOS’ intellectual property rights therein.  Furthermore, DOSE agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of such patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of such patents, to the extent and in jurisdictions where permitted by law.

 

7.2.                            GLAUKOS acknowledges that DOSE is the sole owner of the Dose Licensed Patents, and GLAUKOS agrees that it does not obtain any interest in such patents except for the rights granted herein.  GLAUKOS agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by DOSE of the Dose Licensed Patents, or DOSE’s intellectual property rights therein.  Furthermore, GLAUKOS agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law.

 

7.3.                            DOSE, in its sole discretion and at its own expense, shall control the entire patent process relating to the Dose Licensed Patents and the Glaukos Group 2 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that DOSE agrees to (i) promptly provide copies of all prosecution documents to GLAUKOS upon request; (ii) provide GLAUKOS an opportunity to contribute to the prosecution of claims relating to the Glaukos Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to GLAUKOS, including paying any and all maintenance fees and annuities; and (iv) notify GLAUKOS in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to GLAUKOS, and if requested by GLAUKOS, assign such patent or application to GLAUKOS to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.3 shall hereby be licensed back to the DOSE on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Glaukos Field of Use.    With respect to the Glaukos Group 2 Licensed Patents, GLAUKOS will, among other things, assist DOSE in exercising its rights hereunder to

 

7











 

control the entire patent process related to the Glaukos Group 2 Patents, and GLAUKOS hereby irrevocably designates and appoints DOSE as its agent and attorneys-in-fact, coupled with an interest, to act for and on GLAUKOS’ behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing provisions of this Section 7.3 with the same legal force and effect as if executed by GLAUKOS.

 

7.4.                            GLAUKOS, in its sole discretion and at its own expense, shall control the entire patent process relating to the Glaukos Group 1 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that GLAUKOS agrees to (i) promptly provide copies of all prosecution documents to DOSE upon request; (ii) provide DOSE an opportunity to contribute to the prosecution of claims relating to the Dose Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to DOSE, including paying any and all maintenance fees and annuities; and (iv) notify DOSE in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to DOSE, and if requested by DOSE, assign such patent or application to DOSE to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.4 shall hereby be licensed back to GLAUKOS on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Dose Field of Use.

 

8.                                      TERM

 

8.1.                            This Agreement shall remain in effect until the expiration date of the last expiring of the Dose Licensed Patents, Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents.

 

8.2.                            Notwithstanding the foregoing, Sections 1, 5, 6, 8.2, 11, 12 and 13 shall survive any expiration of this Agreement.

 

9.                                      ENFORCEMENT OF PATENTS

 

9.1.                            Each party agrees that if it becomes aware of any infringement of any of the rights belonging to the other party that are subject of this Agreement, it will promptly disclose such information to the other party.

 

9.2.                            Subject to Sections 9.3 and 9.4, each party shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend any patents owned by such party against any infringer.

 

9.3.                            GLAUKOS shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the Dose Licensed Patents and the Glaukos Group 2 Licensed Patents solely in the Glaukos Field of Use.

 

8











 

9.4.                            DOSE shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the Glaukos Group 1 Licensed Patents in the DOSE Field of USE and the Glaukos Group 2 Licensed Patents in any and all applications other than the Glaukos Field of Use.

 

9.5.                            In the event of any action or proceeding under this Section 9, each party agrees to reasonably cooperate with the party taking such action and, at the request of the party taking such action, to give such party all needed information and assistance to file and prosecute such action or proceeding; provided that the acting party shall promptly reimburse the assisting party for all verified out-of-pocket expenses incurred in providing such assistance.  In connection with the foregoing, with respect to any legal action brought under Sections 9.3 or 9.4, each party agrees to join in such action (as necessary to provide standing for such action based on such party’s ownership of the patents at issue) as a party plaintiff if requested to do so by the other party taking such action at such other party’s expense.

 

9.6.                            In resolving any action or proceeding brought by DOSE or GLAUKOS under Sections 9.3 or 9.4, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is outside the scope of such acting party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to any claim contained therein (provided this clause (ii) shall not apply to DOSE’s enforcement or defense of the Glaukos Group 2 Licensed Patents with respect to claims outside the Glaukos Field of Use); (iii) settles any claim as to any patent rights exclusively licensed to the other party hereunder or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.3 or 9.4, respectively, shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

9.7.                            If DOSE with respect to the Dose Licensed Patents or the Glaukos Group 2 Licensed Patents or GLAUKOS with respect to the Glaukos Group 1 Licensed Patents desires to participate in an action brought by the other party under Sections 9.3 or 9.4, respectively, it shall have the right to do so at its own expense; provided such participation is limited to protecting its patent rights licensed hereunder or owned by it (subject to the exclusive licenses granted herein).  The party taking legal action under Sections 9.3 or 9.4 shall consider in good faith any and all concerns or comments by DOSE or GLAUKOS (as the case may be) in exercising its rights under the foregoing sentence.

 

9











 

9.8.                            In resolving any action or proceeding brought by DOSE or GLAUKOS under Section 9.2, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is within the scope of the other party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to claims within the other party’s exclusive license rights hereunder; (iii) settles any claim as to any patent rights exclusively licensed to the other party: or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above, without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.2 shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

10.                               PATENT MARKING

 

Each party agrees to mark, and to require its licensees or sublicensees to mark, each product that is made, used, sold or imported pursuant to the provisions herein with a patent notice in compliance with the applicable statutory requirements.

 

11.                               NO REPRESENTATIONS AND WARRANTIES

 

11.1.                     EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES WHATSOEVER TO THE OTHER PARTY UNDER THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ALL SUCH WARRANTIES ARE HEREBY EXPRESSLY EXCLUDED AND DISCLAIMED TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW.

 

11.2.                     Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by GLAUKOS to DOSE as to the scope or validity of the Glaukos Group 1 Licensed Patents or Glaukos Group 2 Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

11.3.                     Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by DOSE to GLAUKOS as to the scope or validity of the Dose Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

12.                               NOTICES

 

12.1.                     In the event that either GLAUKOS or DOSE sublicenses or assigns any of the rights, obligations or licenses provided under this Agreement or assigns any of the patents licensed hereunder, the assigning or sublicensing party must promptly notify the other party and must identify the third party to whom such assignment or sublicense has been made, including providing a name and contact information of a representative of such third party and a reasonable description of the rights so sublicensed or assigned and/or a list of the patents so assigned.

 

10












 

12.2.                     Any notice, request, demand, or other communication required or permitted to be given under this Agreement shall be in writing and addressed to its addressee at the address set forth above, or such address as a party may specify from time to time.

 

12.3.                     Such notice, request, demand, or other communication shall be deemed to have been duly given (i) at the time of delivery when hand delivered to the other party; or (ii) at the time of confirmed transmission when sent by facsimile at the address and number set forth below, provided that a confirmation copy is sent by overnight or registered or certified mail within twenty-four (24) hours after the fax transmission (any notice given by facsimile shall be deemed received on the next business day if such notice is received after 5:00 p.m. (recipient’s time) or on a non-business day); or (iii) at the time of delivery, or of attempted delivery in the event that delivery cannot be completed due to no fault of the sender, when sent by registered or certified mail or by overnight courier service.

 

13.                               GENERAL PROVISIONS

 

13.1.                     The parties hereby agree that no agency, joint venture or partnership is created by this Agreement, and that neither party shall incur obligations in the name of the other party, except as expressly set forth in this Agreement.

 

13.2.                     This Agreement shall be governed and construed in accordance with the laws of the State of California, and the parties agree that it is executed and delivered in that state.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the parties agree that such action shall be brought in the United States District Court for the Central District of California, or in the State Court for the County of Orange, California, and the parties hereby submit to the exclusive jurisdiction of said Courts.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled, in addition to its court costs or arbitration fees, to such reasonable attorneys’ fees, expert witness fees, and other litigation expenses as shall be fixed by a court of competent jurisdiction.

 

13.3.                     If any provision of this Agreement should be held to be void or unenforceable, in whole or in part, the court or tribunal so holding shall reform the provision to make it enforceable while maintaining the spirit and goal of the provision, and if the court or tribunal finds it cannot so reform that provision, such provision or part thereof shall be treated as severable, leaving valid the remainder of this Agreement.

 

13.4.                     This Agreement, including its exhibits and all documents referenced herein, constitutes the entire understanding and agreement of the parties as to the subject matter herein, and there are no representations, warranties, promises, or undertakings other than those contained herein.  As to the subject matter hereof, this Agreement supersedes and cancels all previous agreements between the parties hereto.  No course of conduct or dealing between the parties shall act as a modification or waiver of any provision of this Agreement, and no waiver or modification of any of the terms or provisions of this Agreement, or failure or delay on the part of either party hereto in insisting upon or enforcing or resorting to any of its powers, rights, remedies, or options hereunder, and no partial or single exercise thereof, shall constitute a waiver of any such powers, rights, remedies or options, unless such waiver be in writing and signed by the party to be charged.

 

11











 

13.5.                     This Agreement shall be binding upon the parties hereto and their respective subsidiaries, affiliates, heirs, legal representatives, successors and permitted assigns.

 

13.6.                     The terms of this Agreement have been negotiated by the parties hereto and the language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent.  This Agreement shall be construed without regard to any presumption or rule requiring construction against the party causing such instrument or any portion thereof to be drafted, or in favor of the party receiving a particular benefit under the Agreement.  No rule of construction will be applied against any party.

 

13.7.                     The headings in this Agreement are intended for convenience only, and shall not be used to interpret the meaning of this Agreement or to determine the rights of the parties.

 

13.8.                     The parties agree that they shall, at any time and from time to time, on the written request of either party, execute and deliver promptly, at the requesting parties’ expense, all such further documents and instruments and shall do or procure to be done, all such further acts and things as may, from time to time, reasonably be required for the purpose of giving full effect to the provisions of this Agreement.

 

13.9.                     From time to time prior to the Effective Date and thereafter, each party hereto has disclosed or may disclose its Confidential Information to the other party.  In addition each party may, from time to time, obtain or have access to the other party’s Confidential Information.  Each party shall maintain (and cause its employees and contractors to maintain) the confidentiality of the other party’s Confidential Information and not to use or disclose such Confidential Information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any Confidential Information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the Confidential Information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s Confidential Information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.  Upon request of the disclosing party, unless the receiving party has a continuing right to use such Confidential Information pursuant to a license granted hereunder, the receiving party agrees to return to the disclosing party all Confidential Information of the disclosing party, or, at the receiving party’s option destroy such Confidential Information and, thereafter, certify immediately to the disclosing party that all such Confidential Information has been returned or destroyed.

 

12











 

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Agreement to be executed, effective as of the Restatement Date.

 

 

	
 
    	
GLAUKOS   CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
Dated:   June 30, 2015
    	
By:
    	
/s/   THOMAS W. BURNS
    
	
 
    	
 
    
	
 
    	
Printed   Name: 
    	
Thomas   W. Burns
    
	
 
    	
 
    
	
 
    	
Title:
    	
President &   CEO
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DOSE   MEDICAL CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
Dated:   June 30, 2015
    	
By:
    	
/s/   RICHARD L. HARRISON
    
	
 
    	
 
    
	
 
    	
Printed   Name: 
    	
Richard   L. Harrison
    
	
 
    	
 
    
	
 
    	
Title:
    	
Chief   Financial Officer
    
					


 

13











 

EXHIBIT A — DOSE LICENSED PATENTS

 

(Status as of June 30, 2015)

 

	
KMOB
   Ref. No.
   DOSE.
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent
   No
    	
 
    	
Issued:
    
	
1C3CP1
    	
 
    	
OCULAR IMPLANT WITH   THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7708711
    	
 
    	
05/04/10
    
	
1C3CP1C1
    	
 
    	
OCULAR IMPLANT WITH   THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8348877
    	
 
    	
01/08/13
    
	
001VRAU
    	
 
    	
APPARATUS AND METHOD   FOR TREATING OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2006200392
    	
 
    	
11/25/09
    
	
001VR2AU
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2009202842
    	
 
    	
04/26/12
    
	
001AUD3
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2012201744
    	
 
    	
12/4/14
    
	
001JPD2
    	
 
    	
OCULAR IMPLANT WITH   THERAPEUTIC DRUG
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
5C1CP1
    	
 
    	
IMPLANT WITH   INTRAOCULAR PRESSURE SENSOR FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7678065
    	
 
    	
03/16/10
    
	
5CCP1DV1
    	
 
    	
METHOD OF MONITORING   INTRAOCULAR PRESSURE AND TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8142364
    	
 
    	
03/27/12
    
	
5CCPDD
    	
 
    	
SYSTEM AND METHOD OF   MONITORING INTRAOCULAR PRESSURE AND TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011QAUD2
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
044A
    	
 
    	
INTRAOCULAR   PHYSIOLOGICAL SENSOR
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
044WO
    	
 
    	
INTRAOCULAR   PHYSIOLOGICAL SENSOR
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
045A
    	
 
    	
IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
045P1WO
    	
 
    	
IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
049PR3
    	
 
    	
INTRAOCULAR DRUG   DELIVERY IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
001P1C2
    	
 
    	
OCULAR IMPLANT WITH   THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    


 

A-1











 

	
KMOB
   Ref. No.
   DOSE.
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent
   No
    	
 
    	
Issued:
    
	
019NP
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
019EP
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
032A
    	
 
    	
INTRAOCULAR   PHYSIOLOGICAL SENSOR
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
032EP
    	
 
    	
INTRAOCULAR   PHYSIOLOGICAL SENSOR
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036NP
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036AU
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036CA
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036CN
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
CN
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036EP
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036IN
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
IN
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036JP
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
036JPD1
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
037NP
    	
 
    	
UVEOSCLERAL DRUG   DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
053PR
    	
 
    	
IMPLANTS FOR RELEASE OF   STABLE DRUG FORMULATIONS TO THE EYE
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    


 

A-2












 

EXHIBIT B — GLAUKOS GROUP 1 LICENSED PATENTS

 

(Status as of June 30, 2015)

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
001A
    	
 
    	
APPARATUS AND METHOD FOR   TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6638239
    	
 
    	
10/28/03
    
	
001C1
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6955656
    	
 
    	
10/18/05
    
	
001C2
    	
 
    	
L-SHAPED IMPLANT WITH   BI-DIRECTIONAL FLOW
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6780164
    	
 
    	
8/24/04
    
	
001C4
    	
 
    	
IMPLANT WITH ANCHOR
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7297130
    	
 
    	
11/20/07
    
	
001CP1
    	
 
    	
GLAUCOMA TREATMENT   DEVICE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6736791
    	
 
    	
5/18/04
    
	
001VAU
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2001245522
    	
 
    	
2/10/06
    
	
001VCA
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2404037
    	
 
    	
10/14/14
    
	
001VCAD1
    	
 
    	
APPARATUS AND METHOD   FOR TREATING AN OCULAR DISORDER
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
001VEP
    	
 
    	
APPARATUS FOR TREATING   GLAUCOMA
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
001EPD2
    	
 
    	
IMPLANT FOR TREATING   OCULAR DISORDERS
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
001VREP
    	
 
    	
APPARATUS AND METHOD FOR   TREATING GLAUCOMA
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
2078516
    	
 
    	
01/02/13
    
	
001VJP
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
3985019
    	
 
    	
7/20/07
    
	
001VRJP
    	
 
    	
APPARATUS AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5255214
    	
 
    	
4/26/2013
    
	
011A
    	
 
    	
GLAUCOMA STENT AND METHODS   THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7135009
    	
 
    	
11/14/06
    
	
011C1
    	
 
    	
IMPLANT AND METHODS   THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7563241
    	
 
    	
7/21/09
    
	
011C1C1
    	
 
    	
SYSTEM FOR TREATING   OCULAR DISORDERS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8075511
    	
 
    	
12/13/11
    
	
011C1D2C
    	
 
    	
OCULAR IMPLANT DELIVERY   SYSTEM AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011C1DV1
    	
 
    	
SELF-TREPHINING IMPLANT   AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8062244
    	
 
    	
11/22/11
    
	
011C1DV2
    	
 
    	
OCULAR IMPLANT DELIVERY   SYSTEM AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7857782
    	
 
    	
12/28/10
    


 

B-1











 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
011C4
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8579846
    	
 
    	
11/12/13
    
	
011C5
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011C6
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011CP1
    	
 
    	
DEVICES AND METHODS FOR   TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7867186
    	
 
    	
01/11/11
    
	
011CP3
    	
 
    	
OCULAR IMPLANTS WITH   ANCHORS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7431710
    	
 
    	
10/7/08
    
	
011QAU
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2004264913
    	
 
    	
12/08/11
    
	
011QAUD1
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011QCA
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2530234
    	
 
    	
11/25/14
    
	
011QEP
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
DE, ES, FR, GB, IT
    	
 
    	
Issued
    	
 
    	
1651291
    	
 
    	
3/13/2013
    
	
011QEPD1
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
DE, ES, FR, GB, IT
    	
 
    	
Issued
    	
 
    	
2351589
    	
 
    	
11/6/2013
    
	
011QJP
    	
 
    	
DEVICES AND METHODS FOR   GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5249513
    	
 
    	
4/19/2013
    
	
011QJPD1
    	
 
    	
DEVICES FOR GLAUCOMA   TREATMENT
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5698198
    	
 
    	
2/20/15
    
	
011QJPD2
    	
 
    	
DEVICES FOR GLAUCOMA   TREATMENT
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011VAU
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2002258754
    	
 
    	
11/30/06
    
	
011VCA
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2442652
    	
 
    	
01/04/11
    
	
011VCAD1
    	
 
    	
NON-LINEAR DELIVERY   DEVICE AND OCULAR IMPLANT WITH CUTTING MEMBER
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2718294
    	
 
    	
6/17/2014
    
	
011VEP
    	
 
    	
GLAUCOMA STENT FOR   GLAUCOMA TREATMENT
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
011VEPD2
    	
 
    	
SYSTEM FOR TREATING   OCULAR DISORDERS
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
2263621
    	
 
    	
5/20/15
    
	
011VEPD3
    	
 
    	
SYSTEM FOR TREATING   OCULAR DISORDERS
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    


 

B-2











 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
011VJP
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
4264704
    	
 
    	
2/27/09
    
	
011VR2AU
    	
 
    	
IMPLANT AND METHODS   THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2009251058
    	
 
    	
12/5/2013
    
	
011VRAU
    	
 
    	
IMPLANT AND METHODS   THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2006236060
    	
 
    	
1/7/10
    
	
011VRCA
    	
 
    	
SYSTEM AND METHODS   THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2683224
    	
 
    	
12/2/14
    
	
011VRJP
    	
 
    	
SYSTEM FOR TREATMENT OF   OCULAR DISORDERS
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5255402
    	
 
    	
4/26/2013
    
	
011JPD2
    	
 
    	
SYSTEM FOR TREATMENT OF   OCULAR DISORDERS
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
011XEU
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000097431-0001
    	
 
    	
12/27/05
    
	
011XEU2
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000097431-0002
    	
 
    	
12/27/05
    
	
011XEU3
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000097431-0003
    	
 
    	
12/27/05
    
	
013A
    	
 
    	
MEDICAL DEVICE AND   METHODS OF USE FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7094225
    	
 
    	
8/22/06
    
	
013C1
    	
 
    	
MEDICAL DEVICE AND   METHODS OF USE FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7273475
    	
 
    	
9/25/07
    
	
013C1DV1
    	
 
    	
OCULAR IMPLANT WITH   DOUBLE ANCHOR MECHANISM
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8337445
    	
 
    	
12/25/12
    
	
017A
    	
 
    	
GLAUCOMA STENT FOR   TREATING GLAUCOMA AND METHODS OF USE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7331984
    	
 
    	
2/19/08
    
	
017C1
    	
 
    	
IMPLANT DELIVERY SYSTEM   AND METHODS THEREOF FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
017C2
    	
 
    	
IMPLANT DELIVERY SYSTEM   AND METHODS THEREOF FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7879079
    	
 
    	
02/01/11
    
	
020A
    	
 
    	
FLUID INFUSION METHODS   FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7186232
    	
 
    	
3/6/07
    
	
022A
    	
 
    	
COMBINED TREATMENT FOR   CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7163543
    	
 
    	
1/16/07
    


 

B-3











 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
022C1
    	
 
    	
COMBINED TREATMENT FOR   CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7951155
    	
 
    	
5/31/11
    
	
034A
    	
 
    	
TARGETED STENT   PLACEMENT AND MULTI-STENT THERAPY
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7192412
    	
 
    	
3/20/07
    
	
035A
    	
 
    	
OCULAR IMPLANT WITH   ANCHOR AND MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7488303
    	
 
    	
2/10/09
    
	
035C2
    	
 
    	
OCULAR IMPLANT WITH   ANCHOR AND MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
035DV1
    	
 
    	
OCULAR IMPLANT WITH   ANCHORING MECHANISM AND MULTIPLE OUTLETS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8007459
    	
 
    	
8/30/11
    
	
044DA
    	
 
    	
SURGICAL HANDPIECE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
DES490152
    	
 
    	
5/18/04
    
	
044XEU
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0001
    	
 
    	
12/9/03
    
	
044XEU2
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0002
    	
 
    	
12/9/03
    
	
044XEU3
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0003
    	
 
    	
12/9/03
    
	
099A
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8506515
    	
 
    	
08/13/13
    
	
099C1
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
099AUD1
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
099VCA
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
099VEP
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
099VJP
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
099VJPD1
    	
 
    	
UVEOSCLERAL SHUNT AND   METHODS FOR IMPLANTING SAME
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
100A
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6450984
    	
 
    	
9/17/02
    
	
100C1
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6626858
    	
 
    	
9/30/03
    


 

B-4











 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
100C1C1
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6827699
    	
 
    	
12/7/04
    
	
100C1C2
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6827700
    	
 
    	
12/7/04
    
	
100CC1C
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7850637
    	
 
    	
12/14/10
    
	
100CC1C2
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8388568
    	
 
    	
03/05/13
    
	
100CC1CD
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8771217
    	
 
    	
7/8/14
    
	
100CC2C
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8152752
    	
 
    	
04/10/12
    
	
100C7
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
100CPC1
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7220238
    	
 
    	
5/22/07
    
	
113VCA
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2368354
    	
 
    	
2/17/09
    
	
113VEP
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
113VEPD4
    	
 
    	
TRABECULOTOMY DEVICE   AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
113VJP
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
3703721
    	
 
    	
7/29/05
    
	
113VR1JP
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
4688444
    	
 
    	
2/25/11
    
	
113VRCA
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2648346
    	
 
    	
12/4/2012
    
	
113VREP
    	
 
    	
SHUNT DEVICE FOR   TREATING GLAUCOMA
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
1477146
    	
 
    	
8/26/09
    
	
113VREP2
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
113VREP3
    	
 
    	
SHUNT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
DE, FR, GB
    	
 
    	
Issued
    	
 
    	
2116215
    	
 
    	
02/01/12
    


 

B-5












 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
113VRJPD
    	
 
    	
SHUNT DEVICE FOR   TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5323011
    	
 
    	
7/26/2013
    
	
119A
    	
 
    	
STENT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6464724
    	
 
    	
10/15/02
    
	
119C1
    	
 
    	
STENT DEVICE AND METHOD   FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6783544
    	
 
    	
8/31/04
    
	
11CP1C1
    	
 
    	
DEVICES AND METHODS FOR   TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7879001
    	
 
    	
02/01/11
    
	
11CP1C2
    	
 
    	
DEVICES AND METHODS FOR   TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
11CP2CP1
    	
 
    	
OCULAR DISORDER   TREATMENT IMPLANTS WITH MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
11P1C3
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
11P1C4
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
11CP3DV1
    	
 
    	
DRUG ELUTING OCULAR   IMPLANT WITH ANCHOR AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8118768
    	
 
    	
2/21/12
    
	
11P3D1C1
    	
 
    	
OCULAR SYSTEM WITH   ANCHORING IMPLANT AND THERAPEUTIC AGENT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
140A
    	
 
    	
SYSTEM AND METHOD FOR   DELIVERING MULTIPLE OCULAR IMPLANTS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
140CA
    	
 
    	
SYSTEM FOR DELIVERING   MULTIPLE OCULAR IMPLANTS
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
140EP
    	
 
    	
SYSTEM FOR DELIVERING   MULTIPLE OCULAR IMPLANTS
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
140JP
    	
 
    	
SYSTEM FOR DELIVERING   MULTIPLE OCULAR IMPLANTS
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
140NP
    	
 
    	
SYSTEM FOR DELIVERING   MULTIPLE OCULAR IMPLANTS
    	
 
    	
NP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
155A
    	
 
    	
GONIOSCOPE FOR IMPROVED   VIEWING
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8070290
    	
 
    	
12/06/11
    


 

B-6











 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
157DA
    	
 
    	
GONIOSCOPIC SYSTEM   INCLUDING AN OPTICAL ELEMENT ATTACHMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
D645489
    	
 
    	
9/20/11
    
	
171DA
    	
 
    	
GONIOSCOPIC SYSTEM   INCLUDING AN OPTICAL ELEMENT ATTACHMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
D645490
    	
 
    	
9/20/11
    
	
179A
    	
 
    	
SYSTEMS AND METHODS FOR   DELIVERING AN OCULAR IMPLANT TO THE SUPRACHOROIDAL SPACE WITHIN AN EYE
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
179WO
    	
 
    	
SYSTEMS AND METHODS FOR   DELIVERING AN OCULAR IMPLANT TO THE SUPRACHOROIDAL SPACE WITHIN AN EYE
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
196A
    	
 
    	
GLAUCOMA STENT AND   METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
201PR
    	
 
    	
APPARATUS AND METHOD   FOR CONTROLLING PLACEMENT OF INTRAOCULAR IMPLANTS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
205PR
    	
 
    	
GONIOSCOPIC DEVICES
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
207PR
    	
 
    	
STABLE THERAPEUTIC DRUG   COMPOSITIONS AND IMPLANTS FOR DELIVERY OF SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
209PR
    	
 
    	
IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
210PR
    	
 
    	
PUNCTAL IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
212A
    	
 
    	
ANTERIOR CHAMBER DRUG-ELUTING   OCULAR IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
213WO
    	
 
    	
OCULAR IMPLANTS   CONFIGURED TO STORE AND RELEASE STABLE DRUG FORMULATIONS
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
214A
    	
 
    	
IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
214WO
    	
 
    	
IMPLANTS WITH   CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
1C4C11
    	
 
    	
OCULAR IMPLANT WITH   ANCHOR AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8801648
    	
 
    	
8/2/14
    
	
1C4C12
    	
 
    	
METHOD OF DELIVERING AN   IMPLANT FOR TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8333742
    	
 
    	
12/18/12
    
	
1C4C13
    	
 
    	
SYSTEM AND METHOD FOR   TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
1C4C2
    	
 
    	
METHOD OF DELIVERING AN   IMPLANT FOR TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7867205
    	
 
    	
01/11/11
    
	
1C2C3DV1
    	
 
    	
IMPLANT DELIVERY DEVICE   AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Isued
    	
 
    	
8808219
    	
 
    	
8/19/14
    


 

B-7











 

EXHIBIT C — GLAUKOS GROUP 2 LICENSED PATENTS

 

(Status as of June 30, 2015)

 

	
KMOB
   Ref. No.
   GLAUKO3.
    	
 
    	
Title of Invention
    	
 
    	
Status
    	
 
    	
Patent
   No
    	
 
    	
Issued:
    
	
001D1
    	
 
    	
OCULAR IMPLANT WITH   THERAPEUTIC AGENT AND METHODS THEREOF
    	
 
    	
Issued
    	
 
    	
8814820
    	
 
    	
8/26/14
    
	
1C2C3
    	
 
    	
OCULAR IMPLANT WITH   ANCHOR AND THERAPEUTIC AGENT
    	
 
    	
Issued
    	
 
    	
8273050
    	
 
    	
09/25/12
    
	
005A
    	
 
    	
BIFURCATABLE TRABECULAR   SHUNT FOR GLAUCOMA TREATMENT
    	
 
    	
Issued
    	
 
    	
6666841
    	
 
    	
12/23/03
    
	
005C1
    	
 
    	
IMPLANT WITH PRESSURE   SENSOR FOR GLAUCOMA TREATMENT
    	
 
    	
Issued
    	
 
    	
6981958
    	
 
    	
1/3/06
    
	
020C1
    	
 
    	
FLUID INFUSION METHODS   FOR OCULAR DISORDER TREATMENT
    	
 
    	
Issued
    	
 
    	
8617094
    	
 
    	
12/31/13
    
	
020C2
    	
 
    	
FLUID INFUSION METHODS   FOR OCULAR DISORDER TREATMENT
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
022C2
    	
 
    	
COMBINED TREATMENT FOR   CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
Issued
    	
 
    	
8882781
    	
 
    	
11/11/14
    
	
022C3
    	
 
    	
COMBINED TREATMENT FOR   CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
Pending